Low-Dose Enoxaparin in Psoriasis

Zagazig University

Status

Not yet enrolling

Conditions

Psoriasis

Treatments

Drug: Subcutaneous Enoxaparin

Study type

Interventional

Funder types

Other

Identifiers

NCT06416566

Enoxaparin in psoriasis

Details and patient eligibility

About

Rationale:

Psoriasis is a chronic immune-mediated inflammatory skin disorder where T cells play a fundamental role in its pathogenesis.
Low molecular weight heparin has been reported to exert immunomodulatory effect at small doses through inhibition of T cells heparinase enzyme.
Low molecular weight heparin may have promising results for treatment of psoriasis.

Research question:

Can low molecular weight heparin be used safely for treatment of psoriasis with good outcome?
Is enoxaparin inhibitory effect on T cell heparinase enzyme responsible for its beneficial effect?

Hypothesis:

Low molecular weight heparin can achieve good results when used at small doses for treatment of psoriasis.
Heparin can exert immunomodulatory effect in psoriasis through inhibition of T cell heparinase enzyme.

AIM OF WORK

-The aim of this work is to assess the possible clinical efficacy and safety of low-dose enoxaparin in the treatment of psoriasis and to detect if inhibition of heparinase enzyme might account for its beneficial therapeutic effect.

Objectives:

To evaluate safety and efficacy of low molecular weight heparin at small dose for treatment of psoriasis.
Contribute to the ongoing efforts to optimize psoriasis management and improve the lives of individuals affected by this chronic condition.

Enrollment

30 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients with plaque psoriasis, who met the following criteria will be enrolled.
1. Age 18 and above.
2. No systemic (oral, parenteral, photobiological) treatment for psoriasis within the last 2 months.
3. No topical treatment for psoriasis within the last 2 weeks.

Exclusion criteria

1. Pregnancy or lactation. 2. Hypersensitivity to heparin and heparin derivatives and a history of heparin-induced thrombocytopenia.
2. History of bleeding diathesis, uncontrolled hypertension, cerebrovascular accident, peptic ulcer, liver disease and/or abnormal liver function tests or abnormal kidney function tests.
3. History of major surgery within the last 3 months. 5. A family history of bleeding diathesis, or cerebrovascular accident. 6. Concomitant use of oral anticoagulants, acetylsalicylic acid, or other nonsteroidal anti-inflammatory drugs.